202 related articles for article (PubMed ID: 37554093)
1. Comparing adverse events of tenecteplase and alteplase: a real-world analysis of the FDA adverse event reporting system (FAERS).
Shi FE; Yu Z; Sun C; Gao P; Zhang H; Zhu J
Expert Opin Drug Saf; 2024 Feb; 23(2):221-229. PubMed ID: 37554093
[TBL] [Abstract][Full Text] [Related]
2. A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database.
Yang H; Wan Z; Chen M; Zhang X; Cui W; Zhao B
Expert Opin Drug Metab Toxicol; 2023 Apr; 19(4):217-223. PubMed ID: 37243615
[TBL] [Abstract][Full Text] [Related]
3. Novel insights into post-marketing adverse events associated with lenvatinib: A comprehensive analysis utilizing the FAERS database.
Yu Z; Luo J; Wei H
Heliyon; 2024 Mar; 10(6):e28132. PubMed ID: 38524578
[TBL] [Abstract][Full Text] [Related]
4. Comparative safety of tenecteplase vs alteplase for acute ischemic stroke.
Flint AC; Eaton A; Melles RB; Hartman J; Cullen SP; Chan SL; Rao VA; Nguyen-Huynh MN; Kapadia B; Patel NU; Klingman JG
J Stroke Cerebrovasc Dis; 2024 Jan; 33(1):107468. PubMed ID: 38039801
[TBL] [Abstract][Full Text] [Related]
5. Major Bleeding Postadministration of Tenecteplase Versus Alteplase in Acute Ischemic Stroke.
Walton MN; Hamilton LA; Salyer S; Wiseman BF; Forster AM; Rowe AS
Ann Pharmacother; 2023 May; 57(5):535-543. PubMed ID: 36004394
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of tenecteplase in comparison to alteplase in acute ischemic stroke: A systematic review and meta-analysis of randomized controlled trials.
Salamatullah HK; Bashrahil B; Alghamdi AM; Alsharm FS; Alkulli OA; Alzahrani Z; Alkhiri A; Alghamdi S; Makkawi S
Clin Neurol Neurosurg; 2023 Oct; 233():107961. PubMed ID: 37713743
[TBL] [Abstract][Full Text] [Related]
7. A real-world disproportionality analysis of ospemifene: data mining of the public version of FDA adverse event reporting system.
Wen H; Lu C; Zhang M; Qi X
Expert Opin Drug Saf; 2023; 22(11):1133-1142. PubMed ID: 37578751
[TBL] [Abstract][Full Text] [Related]
8. Routine Use of Tenecteplase for Thrombolysis in Acute Ischemic Stroke.
Zhong CS; Beharry J; Salazar D; Smith K; Withington S; Campbell BCV; Wilson D; Le Heron C; Mason D; Duncan R; Reimers J; Mein-Smith F; Diprose WK; Barber PA; Ranta A; Fink JN; Wu TY
Stroke; 2021 Mar; 52(3):1087-1090. PubMed ID: 33588597
[TBL] [Abstract][Full Text] [Related]
9. Tenecteplase use in the management of acute ischemic stroke: Literature review and clinical considerations.
Hailu K; Cannon C; Hayes S
Am J Health Syst Pharm; 2022 Jun; 79(12):944-949. PubMed ID: 35020806
[TBL] [Abstract][Full Text] [Related]
10. A real-world data analysis of acetylsalicylic acid in FDA Adverse Event Reporting System (FAERS) database.
Zhao B; Zhang X; Chen M; Wang Y
Expert Opin Drug Metab Toxicol; 2023; 19(6):381-387. PubMed ID: 37421631
[TBL] [Abstract][Full Text] [Related]
11. Conversion From Intravenous Alteplase to Tenecteplase for Treatment of Acute Ischemic Stroke Across a Large Community Hospital Health System.
Dittmar E; Wolfel T; Menendez L; Pozo J; Ramirez M; Belnap SC; De Los Rios La Rosa F
Ann Pharmacother; 2023 Oct; 57(10):1147-1153. PubMed ID: 36688289
[TBL] [Abstract][Full Text] [Related]
12. Tenecteplase versus alteplase for the treatment of acute ischemic stroke: a meta-analysis of randomized controlled trials.
Huang J; Zheng H; Zhu X; Zhang K; Ping X
Ann Med; 2024 Dec; 56(1):2320285. PubMed ID: 38442293
[TBL] [Abstract][Full Text] [Related]
13. Outcomes with IV tenecteplase and IV alteplase for acute ischemic stroke with or without thrombectomy in real-world settings in the United States.
Qureshi AI; Baskett WI; Bains NK; French BR; Siddiq F; Gomez CR; Shyu CR
J Stroke Cerebrovasc Dis; 2023 Feb; 32(2):106898. PubMed ID: 36493706
[TBL] [Abstract][Full Text] [Related]
14. Effect of Time to Thrombolysis on Clinical Outcomes in Patients With Acute Ischemic Stroke Treated With Tenecteplase Compared to Alteplase: Analysis From the AcT Randomized Controlled Trial.
Singh N; Almekhlafi MA; Bala F; Ademola A; Coutts SB; Deschaintre Y; Khosravani H; Buck B; Appireddy R; Moreau F; Gubitz G; Tkach A; Catanese L; Dowlatshahi D; Medvedev G; Mandzia J; Pikula A; Shankar JJ; Ghrooda E; Poppe AY; Williams H; Field TS; Manosalva A; Siddiqui MM; Zafar A; Imoukhoude O; Hunter G; Shamy M; Demchuk AM; Claggett BL; Hill MD; Sajobi TT; Swartz RH; Menon BK
Stroke; 2023 Nov; 54(11):2766-2775. PubMed ID: 37800372
[TBL] [Abstract][Full Text] [Related]
15. Comparison of pharmacokinetic properties of alteplase and tenecteplase. The future of thrombolysis in acute ischemic stroke.
Marè A; Lorenzut S; Janes F; Gentile C; Marinig R; Tereshko Y; Gigli GL; Valente M; Merlino G
Expert Opin Drug Metab Toxicol; 2024; 20(1-2):25-36. PubMed ID: 38275111
[TBL] [Abstract][Full Text] [Related]
16. Tenecteplase Versus Alteplase for Acute Stroke: Mortality and Bleeding Complications.
Murphy LR; Hill TP; Paul K; Talbott M; Golovko G; Shaltoni H; Jehle D
Ann Emerg Med; 2023 Dec; 82(6):720-728. PubMed ID: 37178103
[TBL] [Abstract][Full Text] [Related]
17. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial.
Kvistad CE; Næss H; Helleberg BH; Idicula T; Hagberg G; Nordby LM; Jenssen KN; Tobro H; Rörholt DM; Kaur K; Eltoft A; Evensen K; Haasz J; Singaravel G; Fromm A; Thomassen L
Lancet Neurol; 2022 Jun; 21(6):511-519. PubMed ID: 35525250
[TBL] [Abstract][Full Text] [Related]
18. Tenecteplase in acute ischemic stroke: Review of the literature and expert consensus from the French Neurovascular Society.
Olindo S; Albucher JF; Bejot Y; Berge J; Cordonnier C; Guillon B; Sablot D; Tardy J; Alamowitch S; Sibon I
Rev Neurol (Paris); 2023 Mar; 179(3):150-160. PubMed ID: 36369068
[TBL] [Abstract][Full Text] [Related]
19. Comparison of dosing errors between tenecteplase and alteplase for management of acute ischemic stroke.
Ray B; Janzen KM; Curran M; Adamson R; Allen L; Warach S; Daley M
J Am Pharm Assoc (2003); 2023; 63(2):643-647. PubMed ID: 36623954
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
